Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the European Commission has granted Orphan Drug Designation to AMX0035, its proprietary fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for…
Agilent Technologies Inc. (NYSE: A) has announced FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced that the U.S. FDA has granted accelerated approval for TECELRA® (afamitresgene autoleucel) as the first engineered cell therapy for treating solid tumors. This…
Novaliq, a biopharmaceutical company specializing in innovative ocular therapies using EyeSol® waterless technology, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued…
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that it has received New Drug Application (NDA) approval from the U.S. Food and Drug Administration (FDA) for its new potassium phosphates in…
Schrödinger, Inc. (Nasdaq: SDGR), renowned for its physics-based computational platform, is launching a new initiative to enhance early-stage drug discovery by predicting toxicology risks. This project aims to improve drug…
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the successful closing of its public offering. The offering comprised 6,665,000 shares of common stock…
BostonGene, a leader in AI-driven molecular and immune profiling solutions, and Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have announced a master agreement…
Samsara Vision, a company dedicated to restoring vision and independence to patients suffering from late-stage age-related macular degeneration (AMD) through advanced visual prosthetic devices, has successfully completed its first SING…
GRO Biosciences Inc. (“GRObio”), a pioneering biotechnology firm utilizing synthetic biology to enhance the amino acid repertoire and advance protein therapeutics, has successfully concluded an oversubscribed Series B financing round,…
Bristol Myers Squibb (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), unveiled new four-year findings from the RHONE-X extension study today. The study successfully met all primary endpoints, underscoring…